

Weekly COVID-19 Breakthrough Infections Report

Clark County, Nevada

Date:September 13, 2022

Breakthrough cases are U.S. residents with a SARS-CoV2 RNA or antigen detected on respiratory specimen collected greater than or equal to 14 days after completing the primary series of an FDA authorized COVID-19 vaccine (i.e., complete vaccination). Complete vaccination is two doses of the Pfizer or Moderna vaccine or one dose of the Johnson and Johnson (Janssen) vaccine.

Exclusion Criteria: The persons who were recently positive for COVID-19, defined as a positive <45 days prior to the current positive test under investigations were excluded.

Given the large number of people being vaccinated in the United States and the high level of ongoing SARS-CoV-2 circulation, thousands of symptomatic vaccine breakthrough cases are expected, even if the vaccines remain as effective as demonstrated during the clinical trials.

Following data have been obtained by matching COVID-19 cases information from Trisano (SNHD's surveillance system) to immunization records from Nevada WebIZ (Immunization database). Data is considered preliminary and subject to change.





Figure 1:Trends in Breakthrough Cases, Deaths and Hospitalizations

Figure 2:Percentage of Cases among 12 Years and Older By Vaccination Status





	Overall			
•	N %	-		
All	118505 10	00		
Age (in years)				
0-4	1	0		
5-11	1444	1		
12-17	5662	5		
18-24	10375	9		
25-49		5		
50-64		24		
65+	20008 1	7		
Gender				
Male		4		
Female		6		
Unknown	909	1		
Race/Ethnicity				
Hispanic	-	20		
White		31		
Black	8978	8		
API	14829 1	3		
AEA	407	C		
Other	8834	7		
Unknown	24731 2	21		
Travel History				
Yes	4560	4		
No		24		
Unknown	86056 7	'3		
Hospitalization				
Yes	2689	2		
No		27		
Unknown	84172 7	'1		
Death				
Yes	1017	1		
No	7603	6		
Unknown	109885 9	93		
Vaccine Type				
Pfizer	78290 6	6		
Unknown	960	1		
Moderna		27		
Janssen	6815	6		
Emergen	1	0		
Underlying Conditions				
Yes	15527 1	3		
No	102978 8	37		

Table 1: Population Characteristics of COVID-19 Breakthrough Cases

Table 2: Breakthrough Case Rates

Fully Vaccinated Population*	Vaccinated Cases	Unvaccinated Population	Unvaccinated Cases	Vaccinated Case Rate per 100K population	Unvaccinated Case Rate per 100K population
1318253	118505	999921	458286	8990	45832

* Please note that the numbers reported for fully vaccinated in the above table may not reflect the total number of completed doses reported on the SNHD dashboard. The CDC considers people to be fully vaccinated 2 weeks after their second dose in a 2-dose series, such as the Pfizer or Moderna vaccines, or 2 weeks after a single-dose vaccine, such as Johnson & Johnson \$ Janssen vaccine.



Table 3:Population Characteristics of COVID-19 Breakthrough Hospitalizations
--

	Overall
	N %
All	2689 100
Age (in years)	
5-11	4 C
12-17	16 1
18-24	28 1
25-49	272 10
50-64	470 17
65+	1899 71
Gender	
Male	1448 54
Female	1237 46
Unknown	4 C
Race/Ethnicity	
Hispanic	338 13
White	1534 57
Black	315 12
API	266 10
AEA	12 0
Other	83 3
Unknown	141 5
Travel History	
Yes	108 4
No	1334 50
Unknown	1247 46
Death	
Yes	729 27
No	440 16
Unknown	1520 57
Vaccine Type	
Pfizer	1566 58
Unknown	61 2
Moderna	837 31
Janssen	225 8
Underlying Conditions	
Yes	1915 71
No	774 29



	Overall
	N %
All	1017 100
Age (in years)	
25-49	32 3
50-64	125 12
65+	860 85
Gender	
Male	600 59
Female	417 41
Race/Ethnicity	
Hispanic	114 11
White	670 66
Black	110 11
API	103 10
AEA	6 1
Other	10 1
Unknown	4 (
Hospitalization	
Yes	729 72
No	66 6
Unknown	222 22
Vaccine Type	
Pfizer	558 55
Unknown	24 2
Moderna	323 32
Janssen	112 11
Underlying Conditions	
Yes	599 59
No	418 41

Table 4: Population Characteristics of COVID-19 Breakthrough Deaths

Table 5: Breakthrough Death Rates

Fully Vaccinated Population	Vaccinated Deaths	Unvaccinated Population	Unvaccinated Deaths	Vaccinated Death Rate per 100K population	Unvaccinated Death Rate per 100K population
1318253	1017	999921	7921	77	792

* Please note that the numbers reported for fully vaccinated in the above table may not reflect the total number of completed doses reported on the SNHD dashboard. The CDC considers people to be fully vaccinated 2 weeks after their second dose in a 2-dose series, such as the Pfizer or Moderna vaccines, or 2 weeks after a single-dose vaccine, such as Johnson & Johnson & Johnson vaccine.



Variable	Outcome	Ν	%
Underlying Medical Condition	Yes	1915	71
	No	774	29
Hypertension	Yes	1233	N/A
Immunocompromised	Yes	113	N/A
Chronic Heart Disease	Yes	577	N/A
Chronic Liver Disease	Yes	48	N/A
Chronic Kidney Disease	Yes	393	N/A
Diabetes	Yes	717	N/A
Neurologic/Neurodevelopmental	Yes	174	N/A
Chronic Lung Disease	Yes	516	N/A
Historically Healthy	Yes	227	N/A

Table 6:Breakdown of COVID-19 Breakthrough Hospitalizations according to Underlying conditions

Table 7:Breakdown of COVID-19 Breakthrough Deaths according to Underlying conditions

Variable	Outcome	Ν	%
Underlying Medical Condition	Yes	599	59
	No	418	41
Hypertension	Yes	389	N/A
Immunocompromised	Yes	47	N/A
Chronic Heart Disease	Yes	216	N/A
Chronic Liver Disease	Yes	19	N/A
Chronic Kidney Disease	Yes	163	N/A
Diabetes	Yes	233	N/A
Neurologic/Neurodevelopmental	Yes	52	N/A
Chronic Lung Disease	Yes	178	N/A
Historically Healthy	Yes	23	N/A

Notes:

* White, Black, Asian, and AEA are non-Hispanic.AEA=American Indian/Eskimos/Alaskan Natives & API=Asian Pacific Islander

* The report does not include breakthrough hospitalizations from State approved facilities as State is responsible for their investigation.

* The breakdown of underlying conditions are not mutually exlusive (i.e., a person can have more than one risk factor).